Skip to main content
main-content

Asthma

Latest articles

06-12-2018 | Asthma | News | Article

Tralokinumab does not reduce corticosteroid use in patients with severe asthma

Findings from the TROPOS trial indicate that treatment with the interleukin-13-targeted monoclonal antibody tralokinumab does not decrease corticosteroid use among patients with severe uncontrolled asthma.

Source:

Eur Respir J 2018; doi:10.1183/13993003.00948-2018

01-11-2018 | Asthma | News | Article

COLUMBA results support long-term use of mepolizumab in patients with severe asthma

The anti-interleukin-5 monoclonal antibody mepolizumab has durable safety and efficacy profiles over an average 3.5 years of follow-up in patients with severe eosinophilic asthma, indicate findings from the COLUMBA open-label extension study.

Source:

J Allergy Clin Immunol 2018; doi:10.1016/j.jaci.2018.09.033

11-10-2018 | Asthma | News | Article

Changing inhaler device does not compromise asthma treatment effectiveness

Results of a real-world study suggest that changing from a dry powder inhaler to a pressurized metered-dose inhaler is not associated with compromised treatment outcomes among patients with asthma.

Source:

J Allergy Clin Immunol Pract 2018; doi:10.1016/j.jaip.2018.09.027

03-10-2018 | Asthma | News | Article

Systemic corticosteroids reduce blood eosinophil counts

Systemic corticosteroid treatment reduces blood eosinophil counts and low levels are maintained for weeks after treatment is discontinued, show real-world data.

Source:

J Asthma 2018; doi:10.1080/02770903.2018.1502301

06-09-2018 | Asthma | News | Article

Single blood eosinophil measure predicts eosinophilic asthma

A single blood eosinophil count could predict persistent eosinophilia in patients with adult-onset asthma, study findings show.

Source:

Respir Med 2018; 141: 81–86

03-09-2018 | Asthma | News | Article

Proportion of asthma patients who could benefit from anti-IL-5 treatment estimated

Researchers estimate that 2% of patients with adult-onset eosinophilic asthma could benefit from treatment involving antibodies against the interleukin-5 pathway.

Source:

J Allergy Clin Immunol Pract 2018; doi:10.1016/j.jaip.2018.05.032

24-07-2018 | Asthma | News | Article

Editor's pick

Proportion of asthma patients who could benefit from anti-IL-5 treatment estimated

Researchers estimate that 2% of patients with adult-onset eosinophilic asthma could benefit from treatment involving antibodies against the interleukin-5 pathway.

Source:

J Allergy Clin Immunol Pract 2018; doi:10.1016/j.jaip.2018.05.032

04-07-2018 | Asthma | News | Article

Editor's pick

Asthma risk prediction score accounts for early treatment response

Researchers have developed a measure for predicting future asthma risk based on patient characteristics and current level of asthma control.

Source:

J Allergy Clin Immunol Pract 2018; Advance online publication

20-06-2018 | Asthma | News | Article

Editor's pick

Good prognosis for patients with mild asthma

Research findings can reassure patients with mild asthma that the long-term prognosis is good, with only a tenth of patients transitioning to more severe disease over 10 years.

Source:

J Allergy Clin Immunol Pract 2018; Advance online publication

08-05-2018 | Asthma | News | Article

Editor's pick

Eosinophilia linked to lung function decline irrespective of asthma symptoms

High blood eosinophil counts are associated with airflow obstruction and lung function decline in patients with asthma, but also in people without respiratory symptoms, population-based study findings show.

Source:

Eur Respir J 2018; Advance online publication

12-03-2018 | Asthma | News | Article

Editor's pick

Exacerbation frequency linked to lung function decline in severe eosinophilic asthma

Repeated exacerbations in patients with severe eosinophilic asthma may be associated with accelerated deterioration of lung function, study findings show.

Source:

J Allergy Clin Immunol Pract 2018; Advance online publication

13-02-2018 | Asthma | News | Article

Editor's pick

Initiation criteria for mepolizumab sufficient for determining long-term benefit

Researchers have been unable to find a reliable rule for identifying patients who are likely to benefit from continued long-term mepolizumab treatment for severe eosinophilic asthma.

Source:

J Allergy Clin Immunol Pract 2017; Advance online publication

16-01-2018 | Asthma | News | Article

Allergic airway inflammation stimulates a dynamic ILC2 phenotype

Researchers have found that the group 2 innate lymphoid cell phenotype is more heterogeneous than previously thought, with a surface marker and gene expression profile that is highly dynamic.

Source:

Front Immunol 2017; Advance online publication

18-12-2017 | Asthma | News | Article

Editor's pick

Increasing physical activity could aid severe asthma management

Researchers recommend addressing inactivity and sedentary time as a possible nonpharmacologic approach to managing severe asthma.

Source:

J Allergy Clin Immunol Pract 2017; Advance online publication

04-10-2017 | Asthma | News | Article

B cells have key role in Th-mediated allergic response

Results of a study conducted in mouse models of allergy suggest that B cells have an important role in propagating T-helper cell-mediated responses to house dust mites.

Source:

J Allergy Clin Immunol. 2017; Advance online publication

04-10-2017 | Asthma | News | Article

Editor's pick

Sex, obesity, and immune disturbances inform severe asthma phenotype in later life

With advancing age, asthma becomes more prevalent in women than men and is associated with obesity, greater airflow limitation, and lower markers of T-helper cell type 2 inflammation, study findings show.

Source:

J Allergy Clin Immunol Pract 2017; Advance online publication

04-10-2017 | Asthma | News | Article

Blood eosinophils vary over time in relation to exacerbation and asthma control

Analysis of the COBRA cohort of adult patients with asthma provides insights into the role eosinophil count plays as a biomarker for predicting exacerbations and treatment efficacy.

Source:

Eur Respir J 2017; 50: 1700019

04-09-2017 | Asthma | News | Article

Japanese subphenotypes of type 2 severe asthma identified

The majority of Japanese patients with severe, difficult-to-treat asthma are likely to present with type 2 asthma and a substantial proportion overlap between two or more subphenotypes, a study suggests.

Source:

J Allergy Clin Immunol Pract 2017; Advance online publication

04-09-2017 | Asthma | News | Article

Gene profiles differ in adult- and childhood-onset severe asthma

A European study suggests gene profiles differ in severe asthma that begins in adulthood rather than childhood, indicating distinct underlying mechanisms at work.

Source:

J Allergy Clin Immunol 2017; Advance online publication

04-09-2017 | Asthma | News | Article

Editor's pick

Global decline in asthma deaths may have stalled

Death rates from asthma among younger people appear to have plateaued in the past decade despite substantial improvements before this, a study in The Lancet suggests.

Source:

Lancet 2017; Advance online publication

image credits